



IR PROCEDURE BLEEDING RISK GUIDANCE

PRE-ASSESSMENT SCREENING

All patients, not on anti-thrombotic therapy, can be initially assessed using the HEMSTOP questionnaire below (each question scores 1 for ves):

- Have you ever consulted a doctor or received treatment for prolonged or unusual bleeding (such as nosebleeds, minor wounds)?
- Do you experience bruises/haematomas larger than 2 cm without trauma or severe bruising after minor trauma?
- After a tooth extraction, have you ever experienced prolonged bleeding requiring medical/dental
- Have you experienced excessive bleeding during or after surgery?
- Is there anyone in your family who suffers from a bleeding disorder (such as haemophilia or von Willebrand disease)?
- Have you ever consulted a doctor or received treatment for heavy or prolonged menstrual periods (contraceptive pill, iron etc.)? (females only)
- Did you experience prolonged or excessive bleeding after delivery? (females only)

If < 2 positive responses:

LOW RISK PROCEDURES: No coagulation screen or FBC required

MODERATE/HIGH RISK PROCEDURES: No coagulation screening required; FBC only

If ≥ 2 positive responses:

Perform coagulation screen (FBC, PT, APTT, Clauss fibrinogen assay) and discuss with haematologist prior to procedure

BLEEDING RISK STRATIFICATION FOR COMMON IR PROCEDURES

LOW RISK INTERVENTIONS

Basic venous interventions (IVC filter insert/removal) Superficial interventions/ biopsies (excluding liver/renal)

GI tract stenting

MSK interventions US guided drainages

Catheter exchange/removal

Arterial interventions (<6F) Arterial interventions (>7F)

Embolisation (TACE/UAE/PAE)

Venous/dialysis access interventions

Tunnel line insertions

HIGH RISK INTERVENTIONS

Aortic stent grafting

Tumour ablation

PCNL/renal biopsy/nephrostomy

TIPSS/TJ liver biopsy

Liver biopsy/biliary intervention

PRE-PROCEDURAL BLOOD PARAMETERS REQUIREMENTS

LOW RISK INTERVENTIONS

No procedure specific

laboratory tests

LIVER DISEASE*

HIGH RISK INTERVENTIONS

Hb: > 70 g/L

Plts: > 50 x 109/L

If on vit K antagonist INR: < 2.0

Hb: > 70 q/L

Plts: > 50 x 109/L Aspirin/ Clopidogrel/Ticagrelor/Prasugrel

If on vit K antagonist INR: < 1.5

Hold duration prior to procedure

Suggest restart time following procedure

Suggest restart time following

procedure

6 h

6-12 h

6-12 h

Suggest restart time following

procedure

12-48 h

1 day

1-3 days

Suggest restart time following

procedure

Evening

Suggest restart time following

procedure

12-24 h

Suggest restart time following

procedure

1 day

Suggest restart time following

procedure

2-3 days

6 h

Suggest restart time following

procedure

Restart after 1 day

6 h

6 h

Suggest restart time following

procedure

Restart after 2-3 days

12-24 h

12-24 h

Does not need to be stopped N/A

PRE-PROCEDURAL ANTI-THROMBOTIC MEDICATION INSTRUCTIONS*

2. Follow local Trust policy for referral to bridging clinic

1. Cardiac stents and stroke or thrombosis within 3 months; consult appropriate clinical team

3. Bleeding and thrombosis risks should be discussed as part of the consent process

HEPARINS: Low Risk Procedures

Hold duration prior to procedure

2-4 h

12 h

1 day

HEPARINS: Moderate/High Risk Procedures

Hold duration prior to procedure

4 h

12 h

1 day Vitamin K Antagonists: Low Risk Procedures | INR < 2.0 on day of procedure

Hold duration prior to procedure

2-3 days

Hold duration prior to procedure

5 days

Thrombin Inhibitors: Low Risk Procedures (as per PAUSE protocol)

Hold duration prior to procedure

1 day if eGFR > 50

2 days if eGFR < 50

2-4 h

Hold duration prior to procedure

2 days if eGFR > 50

4 days if eGFR<50

Factor Xa Inhibitors: Low Risk Procedures (as per PAUSE protocol

Hold duration prior to procedure

Omit 1 day prior

1 day

2 days Factor Xa Inhibitors: Moderate/High Risk Procedures (as per PAUSE protocol)

Hold duration prior to procedure

Omit 2 days prior

1 day

2 days

Aspirin & ADP Receptor Inhibitors: Low Risk Procedures

*CONSIDERATIONS:

Unfractionated Heparin

LMWH (prophylactic)

LMWH (therapeutic)

Unfractionated Heparin

LMWH (prophylactic)

LMWH (therapeutic)

Warfarin/Acenocoumarol

Warfarin/Acenocoumarol

Dabigatran

Argatroban

Dabigatran

Argatroban

Apixaban/Rivaroxaban/Endoxaban

Fondaparinux (prophylactic)

Fondaparinux (therapeutic)

Apixaban/Rivaroxaban/Endoxaban

Fondaparinux (prophylactic)

Fondaparinux (therapeutic)

Aspirin & ADP Receptor Inhibitors: Moderate/High Risk Procedures

	Hold duration prior to procedure	Suggest restart time following procedure
Aspirin (low dose monotherapy)	Does not need to be stopped	N/A
Clopidogrel/Ticagrelor/Prasugrel	7 days	1 day

Consider correction if:

Fibrinogen: < 1.2 g/L

Plts: < 50 x 109/L

Haematocrit < 25%

Authors: Clare Bent and Rai Das on behalf of the BSIR Safety and Quality Committee. Keith Gomez and Will Lester on behalf of the BSIH Haemostasis and Thrombosis Task Force. We acknowledge Raham Karimaghaei for his contributions to this guidance.

^{*} Neither PT nor INR correlate well with bleeding risk in patients with liver disease